Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Clinical Advances in Cardiovascular Interventions
share announcement

Clinical Advances in Cardiovascular Interventions

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 23 June 2024 | Viewed by 494

Special Issue Editor

Dr. Tomasz Tokarek

E-Mail Website
Guest Editor
1. Center for Invasive Cardiology, Electrotherapy and Angiology, Kilinskiego 68, Nowy Sacz, Poland
2. Center for Innovative Medical Education, Jagiellonian University Medical College, Medyczna 9, Krakow, Poland
Interests: coronary artery disease; myocardial infarction; heart failure; atrial fibrillation; aortic stenosis; transcatheter aortic valve disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiovascular diseases are still a major cause of morbidity and mortality throughout the world. To address the rising burden of cardiovascular diseases, we would like to encourage researchers and clinicians alike to submit their pivotal studies on advances in cardiovascular interventions.

It is our great privilege to invite you to contribute to this Special Issue. We aim to publish well-designed studies that can exert a high level of impact on the evidence base of cardiovascular diseases. The long-term goal of this Special Issue is to a create scientific environment able to create studies exploring current clinical practice in percutaneous coronary interventions, valvular heart diseases, arrhythmias, and other cardiovascular interventions. Additionally, and equally important, consideration will be given to studies that focus on new techniques and methods used in the diverse array of cardiovascular interventions.

We aim to publish ground-breaking research articles of significant clinical and scientific value, including observational studies, clinical trials, and review articles. Unique clinical cases, particularly supported by advanced imaging, are also welcome.

Dr. Tomasz Tokarek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary artery disease
  • myocardial infarction
  • cardiovascular imaging
  • microvascular disease
  • heart failure
  • atrial fibrillation
  • ventricular arrhythmias
  • cardiac implantable electronic device
  • valvular heart disease and treatment
  • peripheral arterial disease

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1762 KiB  
Article
Long-Term Mortality after Transcatheter Edge-to-Edge Mitral Valve Repair Significantly Decreased over the Last Decade: Comparison between Initial and Current Experience from the MiTra Ulm Registry
by Nicoleta Nita, Marijana Tadic, Johannes Mörike, Michael Paukovitsch, Dominik Felbel, Mirjam Keßler, Matthias Gröger, Leonhard-Moritz Schneider and Wolfgang Rottbauer
J. Clin. Med. 2024, 13(8), 2172; https://doi.org/10.3390/jcm13082172 - 10 Apr 2024
Viewed by 334
Abstract
(1) Objective: We aimed to assess whether the candidate profile, the long-term outcomes and the predictors for long-term mortality after transcatheter edge-to-edge mitral valve repair (M-TEER) have changed over the last decade; (2) Methods: Long-term follow-up data (median time of 1202 [...] Read more.
(1) Objective: We aimed to assess whether the candidate profile, the long-term outcomes and the predictors for long-term mortality after transcatheter edge-to-edge mitral valve repair (M-TEER) have changed over the last decade; (2) Methods: Long-term follow-up data (median time of 1202 days) including mortality, MACCE and functional status were available for 677 consecutive patients enrolled in the prospective MiTra Ulm registry from January 2010 to April 2019. The initial 340 patients treated in our institution before January 2016 were compared with the following 337 patients; (3) Results: Patients treated after 2016 showed significantly less ventricular dilatation (left ventricular end-systolic diameter of 43 ± 13 mm vs. 49 ± 16 mm, p < 0.007), lower systolic pulmonary pressures (50 ± 15 mmHg vs. 57 ± 21 mmHg, p = 0.01) and a lower prevalence of severe tricuspid regurgitation (27.2% vs. 47.3%, p < 0.001) at baseline than patients treated before 2016. Compared to the cohort treated before 2016, patients treated afterwards showed a significantly lower all-cause 3-year mortality (29.4% vs. 43.8%, p < 0.001) and lower MACCE (38.6% vs. 54.1%, p < 0.001), without differences for MR etiology. While severe tricuspid regurgitation and NYHA class IV remained independently associated with an increased long-term mortality over the last decade, severe left ventricular dilatation (hazard ratio, HR 2.12, p = 0.047) and severe pulmonary hypertension (HR 2.18, p = 0.047) were predictors of long-term mortality only in patients treated before 2016. (4) Conclusions: The M-TEER candidates are currently treated earlier in the course of disease and benefit significantly in terms of a better long-term survival than patients treated at the beginning of the M-TEER era. Full article
(This article belongs to the Special Issue Clinical Advances in Cardiovascular Interventions)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop